XM does not provide services to residents of the United States of America.
A
A

APERAM

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Citi says weak Q3 for European steel already priced in by consensus

BUZZ-Citi says weak Q3 for European steel already priced in by consensus ** Citi sees earnings weakness in the seasonally soft Q3 for European steel, but expects that to already be taken into consideration by consensus estimates ** It points out that European steel prices have remained resilient amid falling raw material prices, leading to small recovery in spot steel margins ** The brokerage sees recovery in spreads as a "precursor to steel market recovery", which could potentially firm up late
A
A
O
S
S
T
V

Arkema, Man Group, Shell

EUROPE RESEARCH ROUNDUP- Arkema, Man Group, Shell Aug 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Arkema, Man Group and Shell, on Friday. HIGHLIGHTS * Arkema SA AKE.PA : HSBC raises target price to EUR 105 from EUR 103 * Berkeley Group BKGH.L : Jefferies raises target price to 4,936p from 4,834p * Diageo Plc DGE.L : Morgan Stanley cuts target price to 2200p from 2380p * Man Group Plc EMG.L : Peel Hunt cuts to add from buy * Sh
A
A
A
A
A
B
B
B
B
B
C
C
C
D
E
E
M
R
S
S
U
A
B
T

Aperam jumps as Q2 report shows 'first signs of anticipated recovery'

BUZZ-Aperam jumps as Q2 report shows 'first signs of anticipated recovery' ** Shares in Aperam APAM.AS rise about 5% after it reported stronger-than-expected Q2 results ** French steelmaker's Q2 adjusted EBITDA beats consensus by 6%, helped by a double-digit "inventory revaluation gain", J.P.Morgan says ** "First signs of the anticipated recovery,"
A
J

Aperam Q2 Sales Reach 1.63 Billion Euros

BRIEF-Aperam Q2 Sales Reach 1.63 Billion Euros Aug 1 (Reuters) - Aperam SA APAM.AS : NET INCOME OF EUR 59 MILLION IN Q2 2024 ADJUSTED EBITDA OF EUR 86 MILLION IN Q2 2024 OUTLOOK: Q3 2024 EBITDA IS EXPECTED AT A SLIGHTLY HIGHER LEVEL VERSUS Q2 2024 SHIPMENTS OF 583 THOUSAND TONNES IN Q2 2024 REMAINED BROADLY STABLE Q/Q OUTLOOK: WE GUIDE FOR HIGHER Q
A

Barclays, Mips AB, Novo Nordisk

EUROPE RESEARCH ROUNDUP-Barclays, Mips AB, Novo Nordisk July 19 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Barclays, Mips AB and Novo Nordisk on Friday. HIGHLIGHTS * Barclays BARC.L : Jefferies raises target price to 341p from 335p * Mips AB MIPS.ST : Jefferies raises to buy from hold * Novo Nordisk NOVOB.CO : HSBC raises target price to DKK 1150 from DKK 1030 * Spectris SXS.L : HSBC raises target price to 3750p from 3425p * S
A
A
B
B
B
B
B
C
D
E
E
E
G
H
H
H
K
S
S
S
T
A
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.